{
  "source": "PA-Notification-Vyndaqel-Vyndamax.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1283-8\nProgram Prior Authorization/Notification\nMedication Vyndaqel® (tafamidis meglumine) and Vyndamax™ (tafamidis)\nP&T Approval Date 6/2019, 2/2020, 2/2021, 2/2022, 2/2023, 9/2023, 9/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nVyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are transthyretin stabilizers indicated\nfor the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated\namyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related\nhospitalization.\n2. Coverage Criteriaa:\nA. Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)\n1. Initial Authorization\na. Vyndaqel/Vyndamax will be approved based on both of the following criteria:\n(1) Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)\n-AND-\n(2) Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted\ntherapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis),\nOnpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vyndaqel/Vyndamax will be approved based on both of the following criteria:\n(1) Documentation that the patient has experienced a positive clinical response to\nVyndaqel/Vyndamax (e.g., improved symptoms, quality of life, slowing of disease\nprogression, decreased hospitalizations, etc.)\n-AND-\n(2) Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted\ntherapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis),\nOnpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. A",
    "dates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Medical Necessity may be in place\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vyndaqel and Vyndamax [package insert]. Pfizer, Inc: New York, NY; October 2023.\n2. Kittleson MM, Maurer MS, et al. American Heart Association Heart Failure and\nTransplantation Committee of the Council on Clinical Cardiology. Cardiac\nAmyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the\nAmerican Heart Association. Circulation. 2020 Jul 7;142(1):e7-e22.\n3. Kittleson, M, Ruberg, F. et al. 2023 ACC Expert Consensus Decision Pathway on\nComprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A\nReport of the American College of Cardiology Solution Set Oversight\nCommittee. JACC. 2023 Mar, 81 (11) 1076–1126.\nProgram Prior Authorization/Notification - Vyndaqel® (tafamidis meglumine) and\nVyndamax™ (tafamidis)\nChange Control\n6/2019 New program.\n2/2020 Updated program to address potential combination amyloidosis treatment.\n2/2021 Annual review with no change to coverage criteria. Updated reference.\n2/2022 Annual review with no change to clinical criteria. Updated reference.\n2/2023 Annual review with no change to coverage criteria. Added state mandate\nfootnote.\n8/2023 Added reference to support requirement that Vyndamax/Vyndaqel are not\nused in combination with another agent for cardiac amyloidosis.\n9/2024 Annual review. Renamed and added examples of RNA-targeted therapies\nfor ATTR amyloidosis. Updated and added references.\n1/2025 Update",
    " in combination with another agent for cardiac amyloidosis.\n9/2024 Annual review. Renamed and added examples of RNA-targeted therapies\nfor ATTR amyloidosis. Updated and added references.\n1/2025 Updated criteria for monotherapy use. Added example of RNA-targeted\ntherapy for ATTR amyloidosis. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}